BAX channel activity mediates lysosomal disruption linked to Parkinson disease

Autophagy

Volumn 10, Issue 5, 2014, Pages 889-900

  Bové, Jordi ^a   Martínez Vicente, Marta ^a   Dehay, Benjamin ^a,e   Perier, Celine ^a   Recasens, Ariadna ^a   Bombrun, Agnes ^b   Antonsson, Bruno ^b   Vila, Miquel ^a,c,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b MERCK SERONO S A   (Switzerland)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

BAX channel inhibitor; Lysosome; Mitochondria; MPTP; Neurodegeneration; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; PROTEIN BAX; ION CHANNEL;

ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; CELL FRACTIONATION; CELL PERMEABILIZATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME MEMBRANE; MALE; MITOCHONDRIAL MEMBRANE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; STRIATONIGRAL DEGENERATION; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; INTRACELLULAR MEMBRANE; LYSOSOME; METABOLISM; PATHOLOGY; PERMEABILITY; PHYSIOLOGY; PROTEIN TRANSPORT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BRAIN; CELLS, CULTURED; HUMANS; INTRACELLULAR MEMBRANES; ION CHANNELS; LYSOSOMES; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; PERMEABILITY; PROTEIN TRANSPORT;

EID: 84899765035     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.28286     Document Type: Article

References (42)

1. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M, Bezard E. Lysosomal impairment in Parkinson's disease. Mov Disord 2013; 28:725-32; PMID:23580333; http://dx.doi.org/10.1002/mds.25462
2. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009; 35:385-98; PMID:19505575; http://dx.doi.org/10.1016/j.nbd.2009.05.023
3. Dehay B, Bové J, Rodríguez-Muela N, Perier C, Recasens A, Boya P, Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010; 30:12535-44; PMID:20844148; http://dx.doi.org/10.1523/JNEUROSCI. 1920-10.2010
4. Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E. Loss of P-type ATPase ATP13A2/ PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 2012; 109:9611-6; PMID:22647602; http://dx.doi.org/10.1073/pnas.1112368109
5. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci 2012; 32:4240-6; PMID:22442086; http://dx.doi.org/10. 1523/JNEUROSCI.5575-11.2012
6. Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012; 4:380-95; PMID:22407749; http://dx.doi.org/10.1002/emmm.201200215
7. Vila M, Bové J, Dehay B, Rodríguez-Muela N, Boya P. Lysosomal membrane permeabilization in Parkinson disease. Autophagy 2011; 7:98-100; PMID:21045565; http://dx.doi.org/10.4161/auto.7.1.13933
8. Bové J, Martínez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011; 12:437-52; PMID:21772323; http://dx.doi.org/10.1038/nrn3068
9. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A 2013; 110:E1817-26; PMID:23610405; http://dx.doi.org/10.1073/pnas.1305623110
10. Perier C, Tieu K, Guégan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 2005; 102:19126-31; PMID:16365298; http://dx.doi.org/10. 1073/pnas.0508215102
11. Perier C, Bové J, Wu DC, Dehay B, Choi DK, Jackson-Lewis V, Rathke-Hartlieb S, Bouillet P, Strasser A, Schulz JB, et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A 2007; 104:8161-6; PMID:17483459; http://dx.doi.org/10.1073/pnas.0609874104
12. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 2009; 10:481-94; PMID:19543220; http://dx.doi.org/10.1038/nrn2665
13. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98:2837-42; PMID:11226327; http://dx.doi.org/10.1073/pnas.051633998
14. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 2000; 97:2875-80; PMID:10688892; http://dx.doi.org/10.1073/pnas.040556597
15. Hartmann A, Michel PP, Troadec JD, Mouatt-Prigent A, Faucheux BA, Ruberg M, Agid Y, Hirsch EC. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 2001; 76:1785-93; PMID:11259496; http://dx.doi.org/10.1046/j.1471-4159.2001.00160.x
16. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tet rahydropyridine-induced Parkinson's disease. J Neurosci 2001; 21:9519-28; PMID:11739563
17. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1339-46; PMID:16484678; http://dx.doi.org/10.1152/ajpgi.00509.2005
18. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factorrelated apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem 2007; 282:28960-70; PMID:17686764; http://dx.doi.org/10.1074/jbc.M705671200
19. Kågedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS, Jürgensmeier JM, Ollinger K. Lysosomal membrane permeabilization during apoptosis - involvement of Bax? Int J Exp Pathol 2005; 86:309-21; PMID:16191103; http://dx.doi.org/10.1111/j.0959-9673.2005.00442.x
20. Oberle C, Huai J, Reinheckel T, Tacke M, Rassner M, Ekert PG, Buellesbach J, Borner C. Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes. Cell Death Differ 2010; 17:1167-78; PMID:20094062; http://dx.doi.org/10.1038/ cdd.2009.214
21. Perier C, Bové J, Vila M. Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid Redox Signal 2012; 16:883-95; PMID:21619488; http://dx.doi.org/10.1089/ars.2011.4074
22. Perier C, Vila M. Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2:a009332; PMID:22355801; http://dx.doi.org/10. 1101/cshperspect.a009332
23. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39:889-909; PMID:12971891; http://dx.doi.org/10.1016/S0896-6273(03) 00568-3
24. Ramonet D, Perier C, Recasens A, Dehay B, Bové J, Costa V, Scorrano L, Vila M. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ 2013; 20:77-85; PMID:22858546; http://dx.doi.org/10.1038/cdd.2012.95
25. Boya P. Lysosomal function and dysfunction: mechanism and disease. Antioxid Redox Signal 2012; 17:766-74; PMID:22098160; http://dx.doi.org/10.1089/ ars.2011.4405
26. Hetz C, Vitte PA, Bombrun A, Rostovtseva TK, Montessuit S, Hiver A, Schwarz MK, Church DJ, Korsmeyer SJ, Martinou JC, et al. Bax channel inhibitors prevent mitochondrion-mediated apoptosis and protect neurons in a model of global brain ischemia. J Biol Chem 2005; 280:42960-70; PMID:16219766; http://dx.doi.org/10.1074/jbc.M505843200
27. Peixoto PM, Ryu SY, Bombrun A, Antonsson B, Kinnally KW. MAC inhibitors suppress mitochondrial apoptosis. Biochem J 2009; 423:381-7; PMID:19691447; http://dx.doi.org/10.1042/BJ20090664
28. Perier C, Bové J, Dehay B, Jackson-Lewis V, Rabinovitch PS, Przedborski S, Vila M. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol 2010; 68:184-92; PMID:20695011
29. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2:141-51; PMID:17401348; http://dx.doi.org/10.1038/nprot.2006.342
30. González-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquère S, Eskelinen EL, Pierron G, Saftig P, Kroemer G. The apoptosis/ autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005; 118:3091-102; PMID:15985464; http://dx.doi.org/10.1242/jcs.02447
31. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008; 9:1004-10; PMID:18971948; http://dx.doi.org/10.1038/ nrm2529
32. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A 1998; 95:5789-94; PMID:9576963; http://dx.doi.org/10.1073/pnas.95.10.5789
33. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr., Hyman BT, Beal MF. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 1998; 18:8145-52; PMID:9763461
34. Dietz GP, Stockhausen KV, Dietz B, Falkenburger BH, Valbuena P, Opazo F, Lingor P, Meuer K, Weishaupt JH, Schulz JB, et al. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J Neurochem 2008; 104:757-65; PMID:17995935
35. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C, Neutzner A, Tjandra N, Youle RJ. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011; 145:104-16; PMID:21458670; http://dx.doi.org/10. 1016/j.cell.2011.02.034
36. Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 2003; 4:365-75; PMID:12728264; http://dx.doi.org/10.1038/nrn1100
37. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22:2780-91; PMID:11923443
38. Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain 2013; 136:2130-46; PMID:23757764; http://dx.doi.org/10.1093/brain/awt131
39. Yuan XM, Li W, Dalen H, Lotem J, Kama R, Sachs L, Brunk UT. Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci U S A 2002; 99:6286-91; PMID:11959917; http://dx.doi.org/10.1073/pnas.092135599
40. Werneburg NW, Guicciardi ME, Bronk SF, Gores GJ. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol 2002; 283:G947-56; PMID:12223355
41. Cuervo AM, Dice JF, Knecht E. A population of rat liver lysosomes responsible for the selective uptake and degradation of cytosolic proteins. J Biol Chem 1997; 272:5606-15; PMID:9038169; http://dx.doi.org/10.1074/jbc.272.9. 5606
42. Storrie B, Madden EA. Isolation of subcellular organelles. Methods Enzymol 1990; 182:203-25; PMID:2156127; http://dx.doi.org/10.1016/0076-6879(90) 82018-W